ALK is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].